2012 and beyond: potential for the start of a second pre-antibiotic era? - PubMed (original) (raw)
Review
doi: 10.1093/jac/dks213. Epub 2012 Jun 11.
Affiliations
- PMID: 22687888
- DOI: 10.1093/jac/dks213
Review
2012 and beyond: potential for the start of a second pre-antibiotic era?
Peter C Appelbaum. J Antimicrob Chemother. 2012 Sep.
Abstract
The past decade has seen an alarming confluence of circumstances antithetical to development of new antibacterials, and most of the very few new drugs under development have problems with their microbiology, toxicity, or pharmacokinetics and pharmacodynamics. Most large pharmaceutical companies have divested themselves of their antibiotic portfolios, and the promise that start-up companies would fill the niche has not been fulfilled. What is left of the field is being stifled by bureaucratic regulations, problems with approval, lack of expertise and a general lack of understanding of how serious the situation is. In paediatrics, in particular, there is no sign of any new antibacterial in the foreseeable future. Waiting for initiatives and deliberations will probably take too long, and a vigorous and deliberate effort to educate the public-who in their turn can apply the needed pressure--seems to be the only way of achieving a rapid turnaround of this most dangerous situation.
Similar articles
- Future antibiotics scenarios: is the tide starting to turn?
Theuretzbacher U. Theuretzbacher U. Int J Antimicrob Agents. 2009 Jul;34(1):15-20. doi: 10.1016/j.ijantimicag.2009.02.005. Epub 2009 Apr 1. Int J Antimicrob Agents. 2009. PMID: 19342202 Review. - Antibacterial resistance: is there a way out of the woods?
Marra A. Marra A. Future Microbiol. 2011 Jul;6(7):707-9. doi: 10.2217/fmb.11.56. Future Microbiol. 2011. PMID: 21797683 No abstract available. - Late stage antibacterial drugs in the clinical pipeline.
Projan SJ, Bradford PA. Projan SJ, et al. Curr Opin Microbiol. 2007 Oct;10(5):441-6. doi: 10.1016/j.mib.2007.08.007. Epub 2007 Oct 22. Curr Opin Microbiol. 2007. PMID: 17950658 Review. - [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese. - Coping with antibiotic resistance: the impending crisis.
Gould IM. Gould IM. Int J Antimicrob Agents. 2010 Nov;36 Suppl 3:S1-2. doi: 10.1016/S0924-8579(10)00497-8. Int J Antimicrob Agents. 2010. PMID: 21129626 Review.
Cited by
- Pipeline of Known Chemical Classes of Antibiotics.
de Souza Mendes Cd, de Souza Antunes AM. de Souza Mendes Cd, et al. Antibiotics (Basel). 2013 Dec 6;2(4):500-34. doi: 10.3390/antibiotics2040500. Antibiotics (Basel). 2013. PMID: 27029317 Free PMC article. Review. - Macroalgal Endophytes from the Atlantic Coast of Canada: A Potential Source of Antibiotic Natural Products?
Flewelling AJ, Ellsworth KT, Sanford J, Forward E, Johnson JA, Gray CA. Flewelling AJ, et al. Microorganisms. 2013 Dec 13;1(1):175-187. doi: 10.3390/microorganisms1010175. Microorganisms. 2013. PMID: 27694771 Free PMC article. - Discovery of sulfone-resistant dihydropteroate synthase (DHPS) as a target enzyme for kaempferol, a natural flavanoid.
Potshangbam AM, Rathore RS, Nongdam P. Potshangbam AM, et al. Heliyon. 2020 Feb 12;6(2):e03378. doi: 10.1016/j.heliyon.2020.e03378. eCollection 2020 Feb. Heliyon. 2020. PMID: 32083215 Free PMC article. - Environmental dissemination of antibiotic resistance genes and correlation to anthropogenic contamination with antibiotics.
Berglund B. Berglund B. Infect Ecol Epidemiol. 2015 Sep 8;5:28564. doi: 10.3402/iee.v5.28564. eCollection 2015. Infect Ecol Epidemiol. 2015. PMID: 26356096 Free PMC article. - Celebrating 75 Years of ASTHO: Milestones in Public Health Leadership.
Maddox N. Maddox N. J Public Health Manag Pract. 2017 Sep/Oct;23(5):524-530. doi: 10.1097/PHH.0000000000000630. J Public Health Manag Pract. 2017. PMID: 28759555 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous